Peabody is a late-stage biotechnology company with a versatile lipid carrier system that delivers better, safer, lasting medications for healthier patients. The Peabody Lipid Carrier System (PLCS) provides consistent plasma concentrations and effective treatment when medication compliance is critical to patient outcome.
The Peabody team is a group of scientific, financial, legal, and business experts with an established success record. Ask our CEO about Peabody’s solutions.
Schedule a callPeabody Pharmaceuticals reformulates existing medications utilizing our patented lipid carrier system to safely deliver therapeutic drug levels continuously for up to 3 days with a single injection.
Our lead development candidate, PBD-2021, is a registration-directed formulation of a potent analgesic, buprenorphine, for the treatment of acute post-operative pain. Buprenorphine is approved by the FDA for the treatment of chronic pain and Opioid Use Disorder. Buprenorphine is a safer and better tolerated alternative to commonly prescribed opioids used to treat acute pain.
Utilizing Peabody’s PLCS carrier, PBD-2021 is designed to address the problems of overdose, misuse, diversion, and accidental pediatric exposure inherent in current opioid prescribing. The acute pain market represents a therapeutic area of substantially unmet need.
Download Peabody's Investor Presentation